Ovid Therapeutics to Present Preclinical Data on TAK-935/OV935 at the Antiepileptic Drug and Device Trials XIV Conference
May 12 2017 - 8:00AM
Ovid Therapeutics Inc., (NASDAQ:OVID) a biopharmaceutical company
committed to developing medicines for patients with rare
neurological diseases, today announced that it will present
preclinical data on TAK-935/OV935, a potent and highly selective
cholesterol 24-hydroxylase inhibitor in development for the
treatment of rare epileptic encephalopathies, at the Antiepileptic
Drug and Device (AEDD) Trials XIV Conference taking place May
17-19, 2017, in Aventura (North Miami Beach), Fla. This will be the
first public presentation of TAK-935 data.
Details of the oral presentation are listed below.
Presentation Session: Session XI: Drug Pipeline
Title: TAK935/OV935, a Novel NMDA Modulator Under
Development for Epileptic
EncephalopathiesPresenter: Matthew During, M.D.,
D.Sc., Ovid TherapeuticsTime: May 19, 2017, 2:10
pm ETLocation: Turnberry Isle Miami Hotel
About TAK-935TAK-935, which is being studied in
rare pediatric epilepsies, is a potent, highly-selective,
first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase
(CH24H). CH24H is predominantly expressed in the brain, where it
plays a central role in cholesterol homeostasis. CH24H converts
cholesterol to 24-S-hydroxycholesterol (24HC), which then exits the
brain into the blood plasma circulation.i Glutamate is one of
the main neurotransmitters in the brain and has been shown to play
a role in the initiation and spread of seizure
activity.ii Recent literature indicates CH24H is involved in
over-activation of the glutamatergic pathway through modulation of
the NMDA channel,iii implying its potential role in CNS
diseases such as epilepsy. To our knowledge, TAK-935 is the only
molecule with this mechanism of action in clinical development.
TAK-935 has been tested in preclinical models to provide data to
support the advancement of the drug into human clinical studies in
patients suffering from rare epilepsy syndromes. A novel
proprietary PET ligand, developed by Takeda and Molecular
Neuroimaging, LLC (MNI), has been used to determine target
occupancy of TAK-935 in the brain.iv In addition, TAK-935’s
effect on CH24H enzyme activity in the brain has been assessed by
following measurable reductions in the plasma concentration
of 24HC.
TAK-935 has completed four Phase 1 clinical
studies,v,vi,vii,viii which have assessed tolerability and
target engagement at doses which are believed to be therapeutically
relevant.
About Ovid TherapeuticsOvid Therapeutics is a
New York-based biopharmaceutical company developing therapies for
patients with rare neurological disorders. Ovid’s drug candidate,
OV101, is currently in development for the treatment of symptoms of
Angelman syndrome and Fragile X syndrome. Ovid is also developing
TAK-935/OV935 in collaboration with Takeda Pharmaceutical Company
Limited for the treatment of rare epileptic encephalopathies.
For more information on Ovid, please visit
http://www.ovidrx.com/.
Forward-Looking Statements
This press release includes certain disclosures which contain
“forward-looking statements,” including, without limitation,
statements regarding the clinical development and scope of clinical
trials, the timing of reporting clinical data for Ovid’s product
candidates, and the potential use of TAK-935/OV935 to treat
epileptic encephalopathies. You can identify forward-looking
statements because they contain words such as “will,” “believes”
and “expects.” Forward-looking statements are based on Ovid’s
current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important factors
that could cause actual results to differ materially from those in
the forward-looking statements are set forth in Ovid’s filings with
the Securities and Exchange Commission, including its registration
statement on Form S-1, as amended, under the caption “Risk
Factors.” Ovid assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
___________________
i Russell DW, Halford RW, Ramirez DMO, Shah R, Kotti T.
Cholesterol 24-hydroxylase: An enzyme of cholesterol turnover in
the brain. Annu Rev Biochem. 2009;78:1017-1040.
ii Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL.
Excitotoxicity: bridge to various triggers in neurodegenerative
disorders. Eur J Pharmacol. 2013;698(1-3):6-18.
iii Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY,
Hammond RS, et al. The major brain cholesterol metabolite
24(S)-hydroxycholesterol is a potent allosteric modulator of
N-methyl-D-aspartate receptors. J Neurosci.
2013;33(44):17290-300.
iv https://www.clinicaltrials.gov/ct2/show/NCT02497235?term=TAK-935&rank=1
v https://www.clinicaltrials.gov/ct2/show/NCT02497235?term=TAK-935&rank=1
vi https://www.clinicaltrials.gov/ct2/show/NCT02906813?term=TAK-935&rank=2
vii https://www.clinicaltrials.gov/ct2/show/NCT02201056?term=TAK-935&rank=3
viii https://www.clinicaltrials.gov/ct2/show/NCT02539134?term=TAK-935&rank=4
Ovid Contacts:
Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2024 to May 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From May 2023 to May 2024